ACG case reports journal
Cure8 research brief
Why This Matters
People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.
This case shows a sequence of biologic and small-molecule therapies plus an off-label GLP-1 analogue that was associated with clinical improvement and reduced stoma losses in one patient.
Who Should Pay Attention
Clinicians treating postcolectomy enteritis, surgeons managing high-output ileostomies, post-surgery IBD patients, and multidisciplinary care teams.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a case report of a 71-year-old man who developed steroid-refractory postcolectomy enteritis with a high-output end ileostomy after subtotal colectomy for acute severe ulcerative colitis. Multiple therapies were tried (corticosteroids, infliximab, upadacitinib, octreotide) without control of ileal inflammation or stoma losses.
Ustekinumab induction was associated with gradual endoscopic, histologic, and radiologic improvement of the enteritis. A glucagon-like peptide-1 (GLP-1) analogue was started off-label to manage the high-output stoma and was followed by reduced stoma output and successful weaning from parenteral nutrition.
This report describes a single patient case and presents a therapeutic sequence rather than comparative evidence. It does not establish effectiveness or safety for broader use but may inform clinicians facing similar complex postcolectomy enteritis cases.
Keep In Mind
Single case report (abstract-level) — no comparative data. GLP-1 analogue use was off-label for high-output stoma. Interpret cautiously.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationACG case reports journal
AuthorsTuttle Z, Wright E, Lust M +3 more
Study typeJournal article, case reports
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 6, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Refractory Crohn's Disease: Effective Therapy by Inhibition of Interleukin 12 and Interleukin 23
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...